Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

44.26
-2.4500-5.25%
Volume:932.00K
Turnover:42.39M
Market Cap:7.43B
PE:114.00
High:46.53
Open:46.51
Low:44.20
Close:46.71
52wk High:55.67
52wk Low:26.99
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.99
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.11
PE(LYR):30.95

Loading ...

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at Sleep 2026

THOMSON REUTERS
·
Jun 18

Alkermes (ALKS) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 16

Alkermes' Sleep Disorder Drug Receives Orphan Drug Status in US and Europe

MT Newswires Live
·
Jun 15

Alkermes says alixorexton enters phase 3 Brilliance trials for narcolepsy type 1, type 2

Reuters
·
Jun 15

Alkermes says FDA grants orphan drug designation for alixorexton in idiopathic hypersomnia

Reuters
·
Jun 15

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

THOMSON REUTERS
·
Jun 15

Alkermes (ALKS) Stock Valuation After New Orphan Drug Designation For Alixorexton

Simply Wall St.
·
Jun 14

Alkermes director Christopher I. Wright disposes of USD 90,200 in common shares

Reuters
·
Jun 13

Should Alkermes’ (ALKS) Sleep-Medicine Pivot After Lumryz and Alixorexton Data Require Investor Action?

Simply Wall St.
·
Jun 12

Alkermes’ alixorexton granted orphan designation for idiopathic hypersomnia

TIPRANKS
·
Jun 12

Mizuho Securities Sticks to Their Buy Rating for Alkermes (ALKS)

TIPRANKS
·
Jun 10

Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says

MT Newswires Live
·
Jun 09

RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating

MT Newswires Live
·
Jun 09

Alkermes Plc : RBC Raises Target Price to $56 From $45

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Jun 08

A Look At Alkermes (ALKS) Valuation After 28.2% Revenue Growth And Strengthening Analyst Optimism

Simply Wall St.
·
Jun 05

Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $87,569.7

Reuters
·
Jun 05

Alkermes to present new data on Alixorexton, LUMRYZ

TIPRANKS
·
Jun 04

Alkermes presents new phase 2 Vibrance-2 data for alixorexton in narcolepsy type 2 at SLEEP 2026

Reuters
·
Jun 04

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)

TIPRANKS
·
Jun 04